Capital BioVentures Announces Inaugural Cohort for Ottawa Biotech Accelerator Program
Summary
Seven innovative enterprises have been chosen to receive assistance ranging from consulting services through the Expert-in-Residence program to lab space placements and non-dilutive funding. The organization is actively looking to expand its lab-space footprint to accommodate additional demand for placements.Capital BioVentures is a not-for-profit biotech accelerator located in Ottawa that offers early-stage funding and resources to Canadian companies. The companys lead asset is an exosome therapy targeting postoperative atrial fibrillation, a serious complication of open chest surgery that results in increased morbidity and healthcare costs. By revealing subtle, previously invisible biomarkers, we empower clinicians to detect early signs of diseases affecting vital organs such as the brain, heart, and kidneys. This enables more accurate diagnoses and timely interventions, leading to improved patient outcomes and reduced healthcare costs.Esphera SynBio: Esphera is a synthetic biology company developing engineered exosomes for the delivery of specific payloads to target cells using a first-in-class proprietary multimeric fusion protein.